Gu, Shuyan Mu, Yiming Zhai, Suodi Zeng, Yuhang Zhen, Xuemei Dong, Hengjin Sensitivity analyses results for dapagliflozin arm versus acarbose arm (results per patient). <p>Sensitivity analyses results for dapagliflozin arm versus acarbose arm (results per patient).</p> healthcare payer perspective;sensitivity analyses;China Objective;treatment-naive patients;Sensitivity analyses;Type 2 Diabetes;40 years;disease burden;treatment comparison;dapagliflozin;hospital surveys;Systematic literature reviews;cost-effectiveness;comparator therapies;type 2 diabetes mellitus;QALY gain;mortality events;Cardiff Diabetes Model;T 2DM;model-required patient profiles;Conclusion Dapagliflozin;alternative medication;Chinese T 2DM patients;acarbose;disease progression;monotherapy 2016-11-02
    https://plos.figshare.com/articles/dataset/Sensitivity_analyses_results_for_dapagliflozin_arm_versus_acarbose_arm_results_per_patient_/4203852
10.1371/journal.pone.0165629.t009